Cocrystal Pharma (COCP) Price Target Increased by 33.33% to 8.16

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks COCP Cocrystal Pharma (COCP) Price Target Increased by 33.33% to 8.16 April 14, 2026 — 11:26 pm EDT Written by George Maybach for Fintel-> The average one-year price target for Cocrystal Pharma (NasdaqCM:COCP) has been revised to $8.16 / share. This is an increase of 33.33% from the prior estimate of $6.12 dated April 7, 2026. The price target is an average of many targets provided by analysts. The latest targets range from a low of $6.06 to a high of $10.50 / share. The average price target represents an increase of 433.33% from the latest reported closing price of $1.53 / share. What is the Fund Sentiment? There are 29 funds or institutions reporting positions in Cocrystal Pharma. This is an decrease of 3 owner(s) or 9.38% in the last quarter. Average portfolio weight of all funds dedicated to COCP is 0.00%, an increase of 5,564.58%. Total shares owned by institutions increased in the last three months by 5.08% to 771K shares. What are Other Shareholders Doing? Renaissance Technologies holds 126K shares representing 0.91% ownership of the company. In its prior filing, the firm reported owning 128K shares , representing a decrease of 1.51%.

Geode Capital Management holds 82K shares representing 0.60% ownership of the company. In its prior filing, the firm reported owning 74K shares , representing an increase of 10.39%. The firm decreased its portfolio allocation in COCP by 15.46% over the last quarter. T3 Companies holds 52K shares representing 0.38% ownership of the company. DRW Securities holds 34K shares representing 0.24% ownership of the company.

Neuberger Berman Group holds 32K shares representing 0.23% ownership of the company. No change in the last quarter. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.Click to Learn MoreThis story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags Stocks Fintel Fintel is a leading provider of financial data and insights for intelligent, data-driven investors. With coverage of over 75,000 listed companies on all major stock exchanges, Fintel has the most comprehensive coverage of global equities at prices individual investors can afford. Check out our Unique Analysis of Insider Sentiment for Cocrystal Pharma, Inc.-> Find out what the Options Markets think of Cocrystal Pharma, Inc.-> See our take on Cocrystal Pharma, Inc. Upcoming Earnings-> More articles by this source-> Stocks mentioned COCP More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.